Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Details
Publication Year 2022-04-23,Volume 34,Issue #6,Page 874-887 e6
Journal Title
Cell Metabolism
Abstract
The tumor microenvironment (TME) contains a rich source of nutrients that sustains cell growth and facilitate tumor development. Glucose and glutamine in the TME are essential for the development and activation of effector T cells that exert antitumor function. Immunotherapy unleashes T cell antitumor function, and although many solid tumors respond well, a significant proportion of patients do not benefit. In patients with KRAS-mutant lung adenocarcinoma, KEAP1 and STK11/Lkb1 co-mutations are associated with impaired response to immunotherapy. To investigate the metabolic and immune microenvironment of KRAS-mutant lung adenocarcinoma, we generated murine models that reflect the KEAP1 and STK11/Lkb1 mutational landscape in these patients. Here, we show increased glutamate abundance in the Lkb1-deficient TME associated with CD8 T cell activation in response to anti-PD1. Combination treatment with the glutaminase inhibitor CB-839 inhibited clonal expansion and activation of CD8 T cells. Thus, glutaminase inhibition negatively impacts CD8 T cells activated by anti-PD1 immunotherapy.
Publisher
Cell Press
Keywords
Keap1; Kras; STK11/Lkb1; glutaminase; glutamine; immune microenvironment; immunotherapy; lung adenocarcinoma; metabolism
WEHI Research Division(s)
Bioinformatics; Cancer Biology And Stem Cells
PubMed ID
35504291
Open Access at Publisher's Site
https://doi.org/10.1016/j.cmet.2022.04.003
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-05-11 10:40:09
Last Modified: 2022-06-16 10:59:16
An error has occurred. This application may no longer respond until reloaded. Reload 🗙